Skip to main content

Estradiol Dosage

Medically reviewed by Drugs.com. Last updated on Dec 19, 2024.

Applies to the following strengths: valerate 40 mg/mL; valerate 10 mg/mL; valerate 20 mg/mL; cypionate 5 mg/mL; 0.05 mg/24 hr; 0.1 mg/24 hr; 0.025 mg/24 hours twice weekly; 0.05 mg/24 hours twice weekly; 0.075 mg/24 hours twice weekly; 0.1 mg/24 hours twice weekly; 0.52 mg/pump (0.06%); 0.75 mg/pump (0.06%); 0.025 mg/24 hours weekly; 0.0375 mg/24 hours twice weekly; 0.5 mg; 1 mg; 2 mg; 0.25 mg/packet (0.1%); 0.5 mg/packet (0.1%); 1 mg/packet (0.1%); 0.05 mg/24 hours weekly; 0.075 mg/24 hours weekly; 0.1 mg/24 hours weekly; 0.0375 mg/24 hours weekly; 0.06 mg/24 hours weekly; 1.5 mg; acetate 0.45 mg; acetate 0.9 mg; acetate 1.8 mg; 1.53 mg/spray; 0.75 mg/packet (0.1%); 1.25 mg/packet (0.1%); benzoate; valerate; 14 mcg/24 hours weekly; hemihydrate

Usual Adult Dose for Postmenopausal Symptoms

ORAL TABLETS:
Initial dose: 1 to 2 mg orally once a day


TRANSDERMAL:
Transdermal Patch TWICE-weekly (Vivelle-Dot, Minivelle, Alora, Dotti, Lyllana):

Transdermal Patch ONCE-weekly (Climara):

Transdermal 0.1% Gel Packets (Divigel):

Transdermal Metered-Dose Pump

Transdermal Spray:

VAGINAL RING:

PARENTERAL:

Comments:

Uses: For the treatment of moderate to severe vasomotor symptoms associated with menopause

Usual Adult Dose for Atrophic Urethritis

ORAL TABLETS:
Initial dose: 1 to 2 mg orally once a day


TRANSDERMAL:
Transdermal Film/Patch TWICE-weekly (Vivelle-dot, Alora, Dotti):

Transdermal Film/Patch ONCE-weekly (Climara):

Transdermal Metered-Dose Pump

VAGINAL RING:

PARENTERAL:

Comments:

Use: For the treatment of moderate to severe symptoms of vulvar and vaginal atrophy associated with menopause

Usual Adult Dose for Atrophic Vaginitis

ORAL TABLETS:
Initial dose: 1 to 2 mg orally once a day


TRANSDERMAL:
Transdermal Film/Patch TWICE-weekly (Vivelle-dot, Alora, Dotti):

Transdermal Film/Patch ONCE-weekly (Climara):

Transdermal Metered-Dose Pump

VAGINAL RING:

PARENTERAL:

Comments:

Use: For the treatment of moderate to severe symptoms of vulvar and vaginal atrophy associated with menopause

Usual Adult Dose for Hypoestrogenism

ORAL TABLETS:
Initial dose: 1 to 2 mg orally once a day


TRANSDERMAL:
Transdermal Film/Patch TWICE-weekly (Vivelle-Dot, Alora, Dotti):

Transdermal Film/Patch ONCE-weekly (Climara):

PARENTERAL:

Comments:

Uses: For the treatment of female hypoestrogenism due to hypogonadism, castration, or primary ovarian failure

Usual Adult Dose for Oophorectomy

ORAL TABLETS:
Initial dose: 1 to 2 mg orally once a day


TRANSDERMAL:
Transdermal Film/Patch TWICE-weekly (Vivelle-Dot, Alora, Dotti):

Transdermal Film/Patch ONCE-weekly (Climara):

PARENTERAL:

Comments:

Uses: For the treatment of female hypoestrogenism due to hypogonadism, castration, or primary ovarian failure

Usual Adult Dose for Primary Ovarian Failure

ORAL TABLETS:
Initial dose: 1 to 2 mg orally once a day


TRANSDERMAL:
Transdermal Film/Patch TWICE-weekly (Vivelle-Dot, Alora, Dotti):

Transdermal Film/Patch ONCE-weekly (Climara):

PARENTERAL:

Comments:

Uses: For the treatment of female hypoestrogenism due to hypogonadism, castration, or primary ovarian failure

Usual Adult Dose for Breast Cancer-Palliative

10 mg orally 3 times a day for at least 3 months

Comments:


Use: For treatment of breast cancer (palliation only).

Usual Adult Dose for Prevention of Osteoporosis

ORAL TABLETS: At least 0.5 orally once a day


TRANSDERMAL:
Transdermal Film/Patch TWICE-weekly (Vivelle-Dot, Minivelle, Alora, Dotti, Lyllana):

Transdermal Film/Patch ONCE-weekly:

Comments:

Use: For the prevention of postmenopausal osteoporosis

Usual Adult Dose for Prostate Cancer

ORAL: 1 to 2 mg orally 3 times a day

PARENTERAL:


Use: For the treatment (palliation only) of advanced androgen-dependent prostate carcinoma

Renal Dose Adjustments

Use with caution in patients with renal dysfunction; estrogens may cause some degree of fluid retention

Liver Dose Adjustments

Contraindicated in patients with hepatic impairment or disease

Precautions

US BOXED WARNINGS: ENDOMETRIAL CANCER, CARDIOVASCULAR DISORDERS, PROBABLE DEMENTIA, and BREAST CANCER - Prescribe estrogens, with or without progestogens, at the lowest effective doses and for the shortest duration consistent with treatment goals and risks for the individual woman:
Estrogen-Alone Therapy:


Estrogen Plus Progestin Therapy:

CONTRAINDICATIONS:

Safety and efficacy have not been established in patients younger than 18 years.

Consult WARNINGS section for additional precautions.

Dialysis

Data not available

Other Comments

Administration advice:


PARENTERAL: IM administration only

TRANSDERMAL: Apply to clean, dry, unbroken skin; wash hands after application; do not apply to breasts

VAGINAL RING:

Storage requirements:

Reconstitution/preparation techniques:

General:

Monitoring:

Patient advice:

See also:

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.